Once largely overlooked, mRNA technology rapidly became a beacon of hope during a global health crisis. Now, it’s attracting attention in the fight against cancer. Despite challenges following the peak of the COVID-19 pandemic and some political resistance, mRNA vaccines continue to advance, offering potential new avenues for treatment.
Subscribe to access the 20-second summary.
Four letters that have gained a Nobel Prize and a swift transition from obscurity to prominence. In a matter of months, mRNA went from being a largely abandoned medical technology – supported by the research of a few early believers – to the world’s primary hope for vaccination against COVID-19. This rapid ascent has also propelled several smaller biotech companies, previously unknown to the general public, to the forefront in the race to develop a solution to end the pandemic, including BioNTech, Moderna, and CureVac.
When initial clinical trials began, many medical observers were cautious, if not skeptical. The technology hadn’t yet been tested in vaccination, and the development timelines seemed far too short. However, the global crisis spurred a surge in scientific studies, government funding, and private investment. Investors were particularly excited by mRNA’s potential in treating other, more lucrative diseases, such as cancer.
Recent research has revealed that mRNA vaccines targeting SARS-CoV-2 can also enhance the effectiveness of cancer immunotherapies. A study published in Nature found that these vaccines stimulate the body’s innate immune system, priming CD8+ T cells to target tumor-associated antigens. The study highlights that combining mRNA vaccines with immune checkpoint inhibitors (ICIs) is most effective in “immunologically cold” tumors, which typically don’t respond well to treatment. These tumors respond by increasing PD-L1 expression.
Researchers observed similar responses in humans, noting increases in type I interferon, myeloid–lymphoid activation in healthy volunteers, and PD-L1 expression on tumors. Importantly, the study found that receiving SARS-CoV-2 mRNA vaccines within 100 days of starting ICI treatment was associated with significantly improved overall survival rates, both in the short and long term. This benefit was consistent even among patients with immunologically cold tumors. These findings suggest that readily available mRNA vaccines, designed for non-cancer related antigens, can powerfully modulate the immune system and make tumors more susceptible to immunotherapy.
Further research, including a study available through PMC, continues to explore the intersection of COVID-19 and cancer, examining the signaling pathways involved. Another study published in The Lancet Oncology demonstrated that most cancer patients undergoing chemotherapy develop an adequate antibody response to the mRNA-1273 COVID-19 vaccine, and the vaccine was found to be safe for these patients. The findings could guide future vaccination strategies for vulnerable populations.
